Serum Tumor Markers, Hypoxia-Inducible factor-1α HIF-1α and Vascular Endothelial Growth Factor, in Patients with Nonsmall Cell Lung Cancer Before and after Intervention

Objective: To explore changes in the serum tumor makers, hypoxia-inducible factor-1α (HIF-1α) and vascularendothelial growth factor (VEGF) level and their relations in patients with non-small cell lung cancer (NSCLC)before and after intervention. Materials and
Methods: Forty patients with NSCLC and 40 healthy individualsundergoing physical examination in our hospital provided the observation and control groups. HIF-1α andVEGF levels in serum were detected by enzyme-linked immuno-sorbent assay (ELISA) in the observationgroup before and after intervention and in control group on the day of physical examination, along with serumcarcino-embryonic antigen (CEA), neuron-speci ic enolase (NSE) and squamous cell carcinoma antigen (SCC)levels in the observation group with a fully automatic biochemical analyzer. Clinical effects and improvement oflife quality in the observation group were also evaluated.
Results: The total effective rate and improvement oflife quality after treatment in observation group were 30.0% and 32.5%, respectively. Serum HIF-1α and VEGFlevels in the control group were lower than that in observation group (p<0.01), but remarkably elevatedafterintervention (p<0.01). In addition, serum CEA, NSE and SCC levels were apparently lowered by treatment(p<0.01). Serum HIF-1αdemonstrated a positive relation with VEGF level (p<0.01) and was inversely relatedwith CEA, NSE and SCC levels (p<0.01).
Conclusions: Significant correlations exist between marked increaseof serum HIF-1α and VEGF levels and decrease of indexes related to hematological tumor markers in NSCLCpatients after intervention.